These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12669126)

  • 1. Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer.
    Luther T; Kotzsch M; Meye A; Langerholc T; Füssel S; Olbricht N; Albrecht S; Ockert D; Muehlenweg B; Friedrich K; Grosser M; Schmitt M; Baretton G; Magdolen V
    Thromb Haemost; 2003 Apr; 89(4):705-17. PubMed ID: 12669126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
    Sato S; Kopitz C; Grismayer B; Beaufort N; Reuning U; Schmitt M; Luther T; Kotzsch M; Krüger A; Magdolen V
    Breast Cancer Res Treat; 2011 Jun; 127(3):649-57. PubMed ID: 20635136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.
    Kotzsch M; Sieuwerts AM; Grosser M; Meye A; Fuessel S; Meijer-van Gelder ME; Smid M; Schmitt M; Baretton G; Luther T; Magdolen V; Foekens JA
    Breast Cancer Res Treat; 2008 Sep; 111(2):229-40. PubMed ID: 17952591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.
    Kotzsch M; Farthmann J; Meye A; Fuessel S; Baretton G; Tjan-Heijnen VC; Schmitt M; Luther T; Sweep FC; Magdolen V; Span PN
    Eur J Cancer; 2005 Nov; 41(17):2760-8. PubMed ID: 16256342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.
    Kotzsch M; Magdolen V; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Eckert AW; Luther T; Baretton G; Würl P; Taubert H
    BMC Cancer; 2011 Jun; 11():273. PubMed ID: 21702998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
    Grismayer B; Sato S; Kopitz C; Ries C; Soelch S; Schmitt M; Baretton G; Krüger A; Luther T; Kotzsch M; Magdolen V
    Biol Chem; 2012 Dec; 393(12):1449-55. PubMed ID: 23667902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
    Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
    Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
    Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
    J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
    Pierga JY; Bonneton C; Magdelénat H; Vincent-Salomon A; Nos C; Boudou E; Pouillart P; Thiery JP; de Cremoux P
    Int J Cancer; 2005 Mar; 114(2):291-8. PubMed ID: 15543615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
    Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer MD; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
    Int J Oncol; 2000 Oct; 17(4):827-34. PubMed ID: 10995898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M; Mourah S; Dosquet C
    Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.